Randomized, Double-Blind, Placebo-controlled Trial Of IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
Sponsor study identifier
interventional
80
0 countries
N/A
Study Start
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This clinical trial will investigate the effect of standardized Irvingia gabonensis extract (IGOB131) on GLP-1 dynamics, DPP-4 activity, metabolic parameters, and inflammatory markers in adults with obesity. The study will compare IGOB131 to a placebo to find out if it exerts any significant metabolic benefits through GLP-1 and DPP-4 modulation, and the reduction of adiposity and systemic inflammation. Participants will: Take IGOB131 or a placebo every day for 16 weeks Visit the clinic once every 4 weeks for checkups and tests
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2, 2026
Actual (reported)October 20, 2026
Actual (reported)December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Effect of IGOB131 on postprandial GLP-1 response (0-180 minutes)
Postprandial GLP-1 responses will be assessed at baseline and week 16 following ingestion of a standardized test meal. Blood samples will be collected at 0 (fasting), 30, 60, 90, 120, 150, and 180 minutes post-meal.
16 weeks
Effect of IGOB131 on fasting plasma GLP-1 concentrations
Blood samples will be collected at 0 (fasting), 30, 60, 90, 120, 150, and 180 minutes post-meal. Plasma GLP-1 concentrations will be measured using a validated enzyme-linked immunosorbent assay (ELISA).
16 weeks
Effect of IGOB131 on DPP-4 enzymatic activity
Fasting venous blood samples will be collected at baseline and at weeks 4, 8, 12, and 16 following an overnight fast (≥10 hours). DPP-4 activity will be determined using a colorimetric assay based on enzymatic cleavage of a specific substrate.
16 weeks
Effect of IGOB131 on fasting blood glucose
16 weeks
Effect of IGOB131 on fasting insulin
16 weeks
Effect of IGOB131 on glycated hemoglobin (HbA1c)
16 weeks
Effect of IGOB131 on homeostatic model assessment for insulin resistance (HOMA-IR)
16 weeks
Effect of IGOB131 on TNF-α
16 weeks
40 participants aged 18-65 with a BMI between 25 - 34 kg/m 2 randomly assigned to the IGOB131 group will be administered 300mg IGOB131 capsule daily for 16 weeks. Participants will be instructed to maintain their usual lifestyle and dietary habits and to report any delays in taking the capsules.
40 participants aged 18-65 with a BMI between 25 - 34 kg/m 2 randomly assigned to the placebo group will be administered a 400 mg dextrin capsule daily for 16 weeks. Participants will be instructed to maintain their usual lifestyle and dietary habits and to report any delays in taking the capsules.
IGOB-131 is an encapsulated, standardized botanical extract derived from Irvingia gabonensis.
Placebo capsules containing 400 mg of dextrin, looking identical to IGOB131 capsules
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patel S, Niazi SK. Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025). Pharmaceutics. 2025 Aug 9;17(8):1036. doi: 10.3390/pharmaceutics17081036.
Ahmad N, Alruwayyes A, Alarjani A, Tawhari A, Aldosri A, Alahmari A, Balaha M. GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2026 Mar 13;105(11):e47994. doi: 10.1097/MD.0000000000047994.
First Submitted
October 2, 2026
First Posted
October 20, 2026
Study Start
December 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 2027
Contact the study team to confirm eligibility.
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017 Feb 8;542(7640):177-185. doi: 10.1038/nature21363.
Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis. 2008 Nov 13;7:44. doi: 10.1186/1476-511X-7-44.
Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids Health Dis. 2009 Mar 2;8:7. doi: 10.1186/1476-511X-8-7.
Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S. doi: 10.1093/ajcn/81.1.230S.
Green BD, Gault VA, O'Harte FP, Flatt PR. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Diabetes Obes Metab. 2005 Sep;7(5):595-604. doi: 10.1111/j.1463-1326.2004.00455.x.
Gasoyan H, Pfoh ER, Schulte R, Le P, Butsch WS, Rothberg MB. One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice. JAMA Netw Open. 2024 Sep 3;7(9):e2433326. doi: 10.1001/jamanetworkopen.2024.33326.
Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Nov;16(11):642-653. doi: 10.1038/s41574-020-0399-8. Epub 2020 Sep 14.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007 Oct;87(4):1409-39. doi: 10.1152/physrev.00034.2006.
Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001.
Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, Bowman JD, Pronk NP. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007 Oct;107(10):1755-67. doi: 10.1016/j.jada.2007.07.017.
Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015 Jul;33(7):673-89. doi: 10.1007/s40273-014-0243-x.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 20, 2026
Record last verified: 2026-10
* Metabolic parameters (Blood sugar, Blood lipid), * Anthroprmetric measures (height, weight, BMI and body fat percentage) * DPP-4 and GLP-1 levels data collected through out the study
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: